CL2024002011A1 - Virus del moquillo canino, composición; y uso. - Google Patents

Virus del moquillo canino, composición; y uso.

Info

Publication number
CL2024002011A1
CL2024002011A1 CL2024002011A CL2024002011A CL2024002011A1 CL 2024002011 A1 CL2024002011 A1 CL 2024002011A1 CL 2024002011 A CL2024002011 A CL 2024002011A CL 2024002011 A CL2024002011 A CL 2024002011A CL 2024002011 A1 CL2024002011 A1 CL 2024002011A1
Authority
CL
Chile
Prior art keywords
cdv
polypeptides
composition
vsv
methods
Prior art date
Application number
CL2024002011A
Other languages
English (en)
Inventor
James Russell Stephen
A Munoz Alia Miguel
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of CL2024002011A1 publication Critical patent/CL2024002011A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos y materiales relacionados con los polipéptidos CDV H y/o CDV F. Por ejemplo, polipéptidos CDV H, polipéptidos CDV F, virus recombinantes (p. ej., virus de estomatitis vesicular (VSV)) que contienen polipéptidos CDV H y/o polipéptidos CDV F, moléculas de ácido nucleico que codifican un polipéptido CDV H y/o un polipéptido CDV F, métodos para producir virus recombinantes (p. ej., VSV) que contienen polipéptidos CDV H y/o polipéptidos CDV F, y se proporcionan métodos para usar virus recombinantes (p. ej., VSV) que contienen polipéptidos CDV H y/o polipéptidos CDV F para tratar el cáncer o enfermedades infecciosas.
CL2024002011A 2019-10-09 2024-07-01 Virus del moquillo canino, composición; y uso. CL2024002011A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962913111P 2019-10-09 2019-10-09

Publications (1)

Publication Number Publication Date
CL2024002011A1 true CL2024002011A1 (es) 2024-12-20

Family

ID=75437513

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2022000902A CL2022000902A1 (es) 2019-10-09 2022-04-08 Virus del moquillo canino hemaglutinina y polipéptidos de fusión
CL2024002011A CL2024002011A1 (es) 2019-10-09 2024-07-01 Virus del moquillo canino, composición; y uso.
CL2024002582A CL2024002582A1 (es) 2019-10-09 2024-08-29 Polipéptidos f y h del virus del moquillo canino (cdv), composición; y uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022000902A CL2022000902A1 (es) 2019-10-09 2022-04-08 Virus del moquillo canino hemaglutinina y polipéptidos de fusión

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024002582A CL2024002582A1 (es) 2019-10-09 2024-08-29 Polipéptidos f y h del virus del moquillo canino (cdv), composición; y uso.

Country Status (16)

Country Link
US (1) US20240066081A1 (es)
EP (1) EP4041752A4 (es)
JP (1) JP2022551486A (es)
KR (1) KR20220079607A (es)
CN (1) CN115605497A (es)
AU (1) AU2020364084A1 (es)
BR (1) BR112022006578A2 (es)
CA (1) CA3156935A1 (es)
CL (3) CL2022000902A1 (es)
CO (1) CO2022004984A2 (es)
IL (1) IL291968A (es)
MX (1) MX2022004384A (es)
PE (1) PE20221166A1 (es)
PH (1) PH12022550836A1 (es)
WO (1) WO2021072284A2 (es)
ZA (1) ZA202203974B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086939A1 (en) * 2018-10-26 2020-04-30 The Wistar Institute Of Anatomy And Biology Canine distemper vaccines and methods of treatment using the same
EP4298228A4 (en) * 2021-02-23 2025-09-24 Mayo Found Medical Education & Res Genetically engineered hemagglutinin and fusion polypeptides from canine distemper virus
CO2021017322A1 (es) * 2021-12-16 2023-06-20 Univ Cooperativa De Colombia Péptidos inmunogénicos contra el virus distemper canino (cdv)
KR20260005359A (ko) * 2023-04-27 2026-01-09 밀테니 비오텍 비.브이. & 씨오. 케이지 개 디스템퍼 바이러스의 외피 단백질로 슈도타이핑된 레트로바이러스 벡터 입자
EP4501946A1 (en) * 2023-07-31 2025-02-05 LoopLab Bio GmbH Self-amplifying biologics for targeted therapy
CN120290491A (zh) * 2025-06-05 2025-07-11 浙江农林大学 一株杂交瘤细胞株、犬瘟热病毒h蛋白单克隆抗体和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375320C (en) * 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
EP1549672B1 (en) * 2002-05-03 2010-09-01 Mayo Foundation For Medical Education And Research Ablated slam-dependent cell entry
WO2013158263A1 (en) * 2012-04-18 2013-10-24 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
EP3625349B1 (en) * 2017-05-16 2024-08-28 Mayo Foundation for Medical Education and Research Modified viruses
EP3679129A1 (en) * 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery

Also Published As

Publication number Publication date
WO2021072284A3 (en) 2021-05-20
CN115605497A (zh) 2023-01-13
CL2022000902A1 (es) 2023-04-21
JP2022551486A (ja) 2022-12-09
IL291968A (en) 2022-06-01
EP4041752A4 (en) 2024-03-20
CA3156935A1 (en) 2021-04-15
PH12022550836A1 (en) 2023-10-09
BR112022006578A2 (pt) 2022-06-28
PE20221166A1 (es) 2022-07-25
ZA202203974B (en) 2025-10-29
CL2024002582A1 (es) 2024-12-20
WO2021072284A9 (en) 2022-04-28
US20240066081A1 (en) 2024-02-29
KR20220079607A (ko) 2022-06-13
WO2021072284A2 (en) 2021-04-15
CO2022004984A2 (es) 2022-04-29
EP4041752A2 (en) 2022-08-17
MX2022004384A (es) 2022-08-08
AU2020364084A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
CL2024002011A1 (es) Virus del moquillo canino, composición; y uso.
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CO2021009271A2 (es) Rhabdovirus recombinante que codifica ccl21
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
ES2061996T3 (es) Regiones no esenciales de avipoxvirus.
CO2020010269A2 (es) Variantes fc con unión mejorada a fcrn y semivida prolongada
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
PE20220429A1 (es) Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a
MX2023011477A (es) Vectores virales para la terapia del cancer.
CL2025001325A1 (es) Construcciones de ácido nucleico, vectores virales y partículas virales
CO2023006544A2 (es) Inmunoterapia oncolítica por remodelación del microambiente tumoral
ES2196032T3 (es) Mutantes y vacunas del virus de la anemia infecciosa de los pollos y utilizaciones basadas sobre las proteinas virales vp1, vp2 y vp3 o secuencias de dicho virus que las codifican.
PE20252442A1 (es) Proteinas de fusion de rsv trimericas estabilizadas sin un dominio de trimerizacion heterologo
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
UY39916A (es) Partículas de aav que comprenden una proteína de la cápside hepatotrópica y alfa-galactosidasa y su uso para tratar la enfermedad de fabry
ES2074422T3 (es) Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
CO2022017351A2 (es) Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80
AR128799A1 (es) Antígenos tumorales, compuestos que comprenden los antígenos tumorales y usos de los mismos
BR112022013620A2 (pt) Vetores adenovirais que codificam antígenos virais da hepatite b fundidos à glicoproteína d do vírus do herpes e métodos de uso dos mesmos
AR119867A1 (es) Gonadotrofina coriónica recombinante, procedimiento para su preparación, composiciones farmacéuticas y usos de la misma
PE20242117A1 (es) Acido nucleico optimizado por codones que codifica la proteina del factor de coagulacion ix, y su uso
JOP20250068A1 (ar) بروتينات piv3 f سابق الإندماج المستقرة
AR131707A1 (es) Composiciones farmacéuticas para la administración de antígenos de glicoproteína c, glicoproteína d y glicoproteína e del virus del herpes simple y métodos relacionados
AR072555A1 (es) Vacuna adenoviral recombinante para elvirus de la leucemia felina y uso de la misma